China’s First HIV Vaccine Enters Phase II Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA approved an application March 23 for an HIV vaccine funded by the Chinese government and developed by Jilin University to proceed to Phase II clinical trials. The trials will enroll 230 healthy people with high risk of HIV infection. The vaccine targets an HIV subtype that was detected in Chinese patients
You may also be interested in...
Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval
SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News
Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval
SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News
AIDS Was Top Killer In China Among Infectious Diseases In 2008, Says Ministry Of Health
SHANGHAI - AIDS became the leading cause of death in China among all infectious diseases in 2008, and claimed 6,897 lives in the first nine months of last year, according to a report issued on the Chinese Ministry of Health's official Web site